Jamjoom Pharma Co. intrinsic value and dividend analysis using DCF, P/B, PEG and PSG models. Includes dividend yield, payout ratio, and dividend sustainability assessment. Sector: PharmaBiotech & Life Science. Listed on Saudi Exchange Tadawul.
Jamjoom Pharmaceuticals Factory Company manufactures and distributes pharmaceutical and consumer health products in Saudi Arabia, the Gulf, Iraq, Egypt, and North Africa. Its product range spans antibiotics, cardiovascular and respiratory medicines, dermatology treatments, and ophthalmic and skincare products. The company was founded in 1994 and is based in Jeddah.
TASIV estimates this company's intrinsic value using a DCF (Discounted Cash Flow) model. As of TASIV's most recent data refresh, the estimated intrinsic value is SAR 109.62 compared to a market price of SAR 137.20 (Trading above DCF model value). This is an analytical estimate, not investment advice.
Revenue increased by about 36% over the three-year period, while net income grew at a faster rate of approximately 59%, indicating that profitability increased faster than sales. Operating cash flow increased by about 37% overall, close to the pace of revenue growth, after a slight dip in the second year followed by a larger increase in the third. Overall, the company's historical financial performance shows growth in revenue, net income, and operating cash flow, with profitability increasing the fastest of the three.
Dividend per share rose every year over the 4-year recorded period, from SAR 1 to SAR 4.2, an increase of about 320%. Payments have been made on a Semi-Annual basis throughout this period. Overall, dividend per share has grown consistently across the recorded period. Current dividend yield is approximately 3.06%, with a payout ratio of approximately 63.39%.
TASIV's Competitive Advantage assessment for this company is High (96/100), based on profitability, predictability, financial strength, and growth resilience.
Based on TASIV's DCF (Discounted Cash Flow) model, the estimated intrinsic value of Jamjoom Pharma Co. is approximately SAR 109.62, compared to a current market price of SAR 137.20. This is an analytical estimate based on the company's financial data, not investment advice or a recommendation to buy or sell.
According to TASIV's model, Jamjoom Pharma Co. is currently "Trading above DCF model value".
Jamjoom Pharma Co.'s dividend yield is approximately 3.06%, with a payout ratio of approximately 63.39%, based on TASIV's most recent verified data.
Loading 4015...